Investor Relations

Ascendis Pharma is applying its innovative prodrug technology to build a leading, fully integrated rare disease company focused on making a meaningful difference in patients’ lives. The company utilizes its TransCon technology with clinically validated parent drugs to create new therapies with potential for best-in-class efficacy, safety and/or convenience. Ascendis Pharma has a wholly-owned pipeline of three rare disease endocrinology product candidates in clinical development.

Stock Information
ASND (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$69.18
Change (%) Stock is Down 1.67 (2.36%)
Volume114,686
Data as of 07/20/18 4:00 p.m. ET
Refresh quote
Stock chart for: ASND.O.  Currently trading at $69.18 with a 52 week high of $76.29 and a 52 week low of $26.30.
Recent NewsMore >>
06/Jun/2018
Ascendis Pharma Announces Orphan Drug Designation Granted for TransCon PTH as Treatment for Hypoparathyroidism
30/May/2018
Ascendis Pharma A/S Reports First Quarter 2018 Financial Results
16/May/2018
Ascendis Pharma A/S Announces First Quarter 2018 Financial Results and Business Update Conference Call on May 30
Upcoming EventsMore >>
There are currently no events scheduled.
Primary IR Contact
Scott T. Smith
Chief Financial Officer
Ascendis Pharma
E-mail: ir@ascendispharma.com

Data provided by Nasdaq. Minimum 15 minutes delayed.